Kim J, Park J, Lim K
At the systemic level, GLP-1 RAs improve insulin sensitivity in peripheral tissues (muscle, adipose), reduce circulating free fatty acid flux to the liver, suppress hypothalamic appetite circuits to promote weight loss, and lower systemic pro-inflammatory cytokines (TNF-, IL-1, IL-6), thereby reducing the hepatic inflammatory milieu indirectly [7,26,30]
Currently, there are limited clinical trials evaluating the efficacy of these two drugs in MASLD
If you qualify for Noom Med, youll be paired with a clinician who can assess your weight loss medication needs and prescribe the right one, if needed
Expert Rev Clin Pharmacol (2021) 14(9):10819